Cargando…

Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens

INTRODUCTION: Based on the variable benefit of taxanes in the adjuvant setting of early breast cancer in certain tumor phenotypes, especially in human epidermal growth factor receptor (HER)2-positive and triple-negative disease, and with the observation of a lesser benefit in luminal A, this researc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kader, Yasser Abdel, El-Nahas, Tamer, Sakr, Amr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745289/ https://www.ncbi.nlm.nih.gov/pubmed/23966793 http://dx.doi.org/10.2147/OTT.S48397

Ejemplares similares

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation
por: Kader, Yasser Abdel, et al.
Publicado: (2013)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer
por: Lichthardt, Sven, et al.
Publicado: (2016)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Comparative Study on the Efficacy of Two Perioperative Chemotherapy Regimens for Lumbar Brucellosis
por: Wang, Jie, et al.
Publicado: (2023)

Adjuvant chemotherapy
por: Glimelius, B.
Publicado: (2013)

Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan
por: Takata, Kosuke, et al.
Publicado: (2016)

Docetaxel, Oxaliplatin and Capecitabine (TEX) triplet regimen as adjuvant chemotherapy in resected gastric adenocarcinoma
por: Thumaty, Divya Bala, et al.
Publicado: (2021)

Abstract 11. The Effect of Neoadjuvant Chemotherapy Compared to Adjuvant Chemotherapy in Nipple-Sparing Mastectomy
por: Frey, Jordan D., et al.
Publicado: (2017)

Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer
por: Fei, Zuo, et al.
Publicado: (2019)

Correlation Between Adjuvant Chemotherapy Regimen, Recurrence Pattern and Prognosis of Cholangiocarcinoma After Radical Surgery
por: Rao, Le, et al.
Publicado: (2022)

Adjuvant chemotherapy for early breast cancer.
por: Henderson, I. C.
Publicado: (1990)

Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors
por: Sobash, Philip T., et al.
Publicado: (2022)

DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer
por: Sigin, Vladimir O., et al.
Publicado: (2023)

Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, p16(INK4a)
por: Shachar, Shlomit S, et al.
Publicado: (2020)

Adjuvant chemotherapy for colorectal cancer
por: Maughan, T S
Publicado: (2001)

A systematic review and network meta-analysis protocol of adjuvant chemotherapy regimens for resected gastric cancer
por: Ge, Long, et al.
Publicado: (2019)

Update on Adjuvant Chemotherapy for Early Breast Cancer
por: Rampurwala, Murtuza M, et al.
Publicado: (2014)

Progress in adjuvant chemotherapy for breast cancer: an overview
por: Anampa, Jesus, et al.
Publicado: (2015)

Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report
por: Jung, Sung Ui, et al.
Publicado: (2021)

Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype(−) Breast Cancer
por: Kim, Hyung Suk, et al.
Publicado: (2019)

The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer
por: Rivas, Mauricio, et al.
Publicado: (2019)

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
por: Thompson, Kevin J, et al.
Publicado: (2022)

Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers
por: Tao, Hao‐Yun, et al.
Publicado: (2022)

The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients
por: Hsieh, Mei‐Chin, et al.
Publicado: (2016)

The efficiency and regimen choice of adjuvant chemotherapy in biliary tract cancer: A STROBE-compliant retrospective cohort study
por: Yin, Luxi, et al.
Publicado: (2018)

Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer: a propensity-matched analysis
por: Quan, RenCui, et al.
Publicado: (2016)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer
por: Huang, Wen-Kuan, et al.
Publicado: (2022)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Adjuvant chemotherapy in head and neck cancer.
por: Stell, P. M., et al.
Publicado: (1990)

Impact of adjuvant chemotherapy for gliomatosis cerebri
por: Kong, Doo-Sik, et al.
Publicado: (2010)

Copper-lowering agents as an adjuvant in chemotherapy
por: Kadu, Pramod, et al.
Publicado: (2021)

Updated Adjuvant Chemotherapy for Gastric Cancer
por: Takayama, Toshizo, et al.
Publicado: (2023)

Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases
por: Horimoto, Y, et al.
Publicado: (2015)

The need to optimize chemotherapy regimens for chemo-immunotherapy
por: Inamura, Kentaro, et al.
Publicado: (2022)

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Posterior Reversible Encephalopathy Syndrome Secondary to R-CHOP Chemotherapy Regimen
por: Jennane, Selim, et al.
Publicado: (2022)

Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis
por: Labrosse, Julie, et al.
Publicado: (2020)

Dose-dense adjuvant chemotherapy for primary breast cancer
por: Fornier, Monica, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_10ghesb6dci57f38aockmk4gib